Overview

• The committee issued a subpoena to Dr. Philip Dormitzer after he declined voluntary cooperation and scheduled his testimony for July 22.
• Lawmakers are probing claims from a GSK letter that senior Pfizer executives intentionally slowed clinical trials so data would not be ready before the election.
• GSK’s human resources letter quoted Dormitzer saying the vaccine’s timing was “not a coincidence” and that top R&D officials directed the slowdown in late 2020.
• Both Dormitzer and Pfizer CEO Albert Bourla have denied any political motive, saying they acted as quickly as possible to secure FDA Emergency Use Authorization.
• Manhattan federal prosecutors have received GSK’s internal allegations, opening a parallel legal review alongside the congressional inquiry.